The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes

Journal of Molecular Medicine

Volumn 76, Issue 1, 1998, Pages 32-47

  Lindauer, Markus ^a,c,d   Stanislawski, Thomas ^a,b   Häußler, Annett ^a   Antunes, Edith ^a   Cellary, Anne ^a   Huber, Christoph ^a   Theobald, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antigen presentation; Cancer immunotherapy; Cytotoxic T lymphocytes; T cell tolerance; Tumor associated peptide antigens

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0031882756     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s109-1998-8102-9     Document Type: Review

References (207)

1. Bretscher PA, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042-1049
2. Schwartz RH (1990) A cell culture model for T lymphocyte cloual anergy. Science 248:1349-1356
3. Kappler JW, Roehm N, Marrack P (1987) T cell tolerance by cloual elimination in the thymus. Cell 49:273-280
4. + thymocytes. Nature 333:742-746
5. Allen PM (1994) Peptides in positive and negative selection: a delicate balance. Cell 76:593-596
6. + T cells. Immunity 3:79-86
7. Munir Alam S, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NRJ (1996) T-cell receptor affinity and thymocyte positive selection. Nature 381:616-620
8. Lehner PJ, Cresswell P (1996) Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 8:59-67
9. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM (1996) Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:429-43
10. Rechsteiner M, Hoffmann L, Dubiel W (1993) The multicatalytic and 26S proteases. J Biol Chem 268:6065-6068
11. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL (1993) A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 363:552-554
12. Cox JH, Galardy P, Bennink JR, Yewdell JW (1995) Presentation of endogenous and exogenous antigens is not affected by inactivation of El ubiquitin-activating enzyme in temperature-sensitive cell lines. J Immunol 154:511-519
13. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel P-M (1995) Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality ot the 20S proteasome polypeptide processing products independent of interferon-γ. Eur J Immunol 25:2605-2611
14. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel P-M (1994) Interferon γ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 179:901-909
15. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschützky H, Jung G, Maier B, Eichmann K (1995) Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2:289-299
16. Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski UH, Kloetzel P-M (1995) The interferon - inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 270:23808-23815
17. Goth S, Nguyen V, Shastri N (1996) Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J Immunol 157:1894-1904
18. Del Val M, Schlicht H-J, Ruppert T, Reddehase MJ, Koszinowski UH (1991) Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on ist neighboring residues in the protein. Cell 66:1145-1153
19. + T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med 176:1335-1341
20. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengede E, Kloetzel P-M, Neefjes J, Koszinowski UH, Melief C (1996) A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5:115-124
21. Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J (1994) Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol 4:769-776
22. Akiyama K, Yokota K, Kagawa S, Shimbara N, Tamura T, Akioka H, Nothwang HG, Noda C, Tanaka K, Ichihara A (1994) cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science 265:1231-1234
23. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, Tonegawa S (1994) Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1:533-541
24. Arnold D, Driscoll P, Androlewicz M, Hughes E, Cresswell P, Spiess TA (1992) Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature 360:171-173
25. Momburg F, Ortiz-Navarrete V, Neefjes J, Goulmy E, Vandewal Y, Spits H, Powis SJ, Butcher GW, Howard JC, Walden P, Hämmerling GJ (1992) The proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 360:174-177
26. Groettrup M, Kraft R, Kostka S, Standera S, Stohwasser R, Kloetzel P-M (1996) A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol 26:863-869
27. Nandi D, Jiang H, Monaco JJ (1996) Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol 156:2361-2364
28. Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, Chung CH, Shibmara N, Wily PJ, Mott JD, et al (1995) Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome. FEBS Lett 366:37-42
29. Groettrup M, Soza A; Eggers M, Kuehn L, Dick TP, Schild H, Rammensee H-G, Koszinowski UH, Kloetzel P-M (1996) A role for the proteasome regulator PA28a in antigen presentation. Nature 381:166-168
30. Dick TP, Ruppert T, Groettrup M, Kloetzel P-M, Kuehn L, Koszinowski UH, Stefanovic S, Schild H, Rammensee H-G (1996) Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86:253-262
31. Udono H, Srivastava PK (1993) Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178:1391-1396
32. Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585-1588
33. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688
34. Restifio NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers defect in antigen processing. J Exp Med 177:265-272
35. Seliger B, Höhne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C (1996) Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56:1756-1760
36. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel P-M, Ehrlich R (1996) LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183:499-514
37. Speiser DE, Kyburz D, Stuebi U, Hengartner H, Zinkernagel RM (1992) Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J Immunol 149:972-980
38. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93:4102-4107
39. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA (1996) Role of antigen. CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184:485-492
40. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993-11997
41. Schumacher TNM, Kantesaria DV, Heemels MT, Ashton-Rickardt PG, Shepherd JC, Früh K, Yang Y, Peterson PA, Tonegawa S, Ploegh HL (1994) Peptide length and sequence specificity of mouse TAP1/TAP2 translocator. J Exp Med 179:533-540
42. Momburg F, Roelse J, Hämmerling GJ. Neefjes JJ (1994) Peptide size selection by the major histocompatibility complex encoded peptide transporter. J Exp Med 179:1613-1623
43. Neisig A, Roelse J, Sijts AJAM, Ossendorp F, Feltkamp MCW, Kast WM, Melief CJM, Neefjes JJ (1995) Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class 1-presentable peptides and the effect of flanking sequences. J Immunol 154:1273-1279
44. Androlewicz MJ, Ortmann B, Van Endert PM, Spiess TA, Cresswell P (1994) Characteristics of peptide and class 1/β2m binding to the transporters associated with antigen processing (TAP.1 and TAP.2). Proc Natl Acad Sci USA 91:12716-12720
45. Van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A. Bach J-F (1995) The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 182:1883-1895
46. Falk K, Rötzschke O, Rammensee HG (1990) Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251
47. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJH, Uytedhaag FGCM, Ploegh HL. Uchanska-Ziegler B, Ziegler A (1994) A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 91:1534-1538
48. Bouvier M, Wiley DC (1994) Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265:398-402
49. Eisenlohr LC, Bacik I, Bennink JR, Bernstein BK, Yewdell YW (1992) Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell 71:963-972
50. Wei ML, Cresswell P (1992) HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443-446
51. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH (1992) HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255:1264-1267
52. Roelse J, Gromme M, Momburg F. Hämmerling GJ, Neefjes JJ (1994) Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med 180:1591-1597
53. Kovacsovics-Bankowski M, Rock KL (1995) A phagosometo-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243-246
54. Reis e Sousa C, Germain RN (1995) Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 182:841-851
55. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wölfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534
56. + T cells. Nature 364:158-161
57. Rotem-Yehudar R, Winograd S, Sela S, Coligan JE, Ehrlich E (1994) Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J Exp Med 180:477-488
58. Cromme FV, Airey J, Heemels M-T, Ploegh HL, Keating PJ, Stern PL, Meijer CJEM, Walboomers JMM (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335-340
59. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL (1995) Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55:5191-5194
60. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 25:1374-1384
61. Sanda MG, Restifio NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM. Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280-285
62. Khanna R, Burrows SR, Argaet V, Moss DJ (1994) Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line. Int J Immunol 6:639-645
63. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415
64. Toes REM, Offringa R, Blom RJJ, Brandt RMP, Van der Eb AJ, Melief CJM, Kast WM (1995) An adenovirus type 5 early region 1B-encoded CTL epitope mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 154:3396-3405
65. Ortmann B, Androlewicz MJ, Cresswell B (1994) MHC class I/β2-microglobulin complexes associate with TAP transporters before peptide binding. Nature 368:864-867
66. Suh W-K, Cohen-Doyle MF, Früh K, Wang KN, Peterson PA, Williams DB (1994) Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 264:1322-1326
67. Grandea AG III, Androlewicz MJ, Athwal RS, Geraghty DE, Spiess TA (1995) Dependence of peptide binding by MHC class I molecules on their interaction with TAP. Science 270:105-108
68. 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med 180:216.3-2171
69. 2-microglobulin. J Biol Chem 270:19638-19642
70. Scott JE, Dawson JF (1995) MHC class I expression and transport in a calnexin-deficient cell line. J Immunol 155:143-148
71. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296
72. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides hound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261-1263
73. Madden DR, Gorga JC, Strominger JL, Wiley DC (1992) The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70:1035-1048
74. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifio NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149-3157
75. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumor development. Immunol Today 14:491-499
76. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494
77. Momburg F, Ziegler A, Harpprecht J, Möller P, Moldenhauer G, Hämmerling GJ (1989) Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol 142:352-358
78. 2microglobulin mRNA in human colon carcinoma. J Exp Med 169:309-314
79. 2-Microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Res 52:1201-1204
80. Ting JPY, Baldwin AS (1993) Regulation of MHC gene expression. Curr Opin Immunol 5:8-16
81. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, Van Lier R. Pfreundschuh M (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833-835
82. Renner C, Bauer S, Sahin U, Jung W, Van Lier R, Jacobs G, Held G, Pfreundschuh M (1996) Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 87:2930-2937
83. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322
84. + effector T cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci 79:4359-4399
85. Irwin MJ, Heath WR, Sherman LA (1989) Species-restricted interactions between CDS and the α3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 179:1091-1101
86. Sun J, Leahy DJ, Kavathas PB (1995) Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the α2 and α3 domains of MHC class I. J Exp Med 182:1275-1280
87. Garcia KC, Scott CA, Brunmark A, Carbone FR, Peterson PA, Wilson IA, Teyton L (1996) CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 384:577-581
88. d-restrieted cytotoxic T lymphocytes. J Exp Med 173:849-858
89. Sherman LA, Hesse SV, Irwin MJ, LaFace DM, Peterson PA (1992) Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258:815-818
90. Davis MM, Chien YH (1993) Topology and affinity of T cell receptor-mediated recognition of peptide-MHC complexes. Curr Opin Immunol 5:45-49
91. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA (1996) An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209-219
92. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134-141
93. Sykulev Y, Brunmark A, Jackson MR, Cohen RJ, Peterson PA, Eisen HN (1994) Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity 1:15-22
94. + cytotoxic T lymphocytes. Proc Natl Acad Sci USA 92:11990-11992
95. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571
96. Schodin BA, Tsomides TJ, Kranz DM (1996) Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity 5:137-146
97. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148-151
98. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798
99. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613-5616
100. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M (1996) T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88:236-241
101. O'Connell JO, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
102. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J (1996) Melanoma cell expression of Fas (Apo-l/CD95) ligand: implications for tumor immune escape. Nature 274:1363-1366
103. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
104. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
105. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1995) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
106. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1995) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352
107. + cytotoxic T lymphocytes. J Exp Med 181:363-368
108. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde K-H, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764
109. Kang X, Kawakami Y. El-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF (1995) Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 155:1343-1348
110. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B. Wölfel T, Boon T, Lethé B (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224-230
111. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965-1971
112. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 183:1131-1140
113. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216
114. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457
115. van der Bruggen P, Szikora J-P, Boël P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur J Immunol 24:2134-2140
116. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930
117. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109
118. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smit C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
119. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld J-C, Coulie P, Boon T, van der Bruggen (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175
120. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698
121. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944-5950
122. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173-1183
123. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284
124. Coulie PG, Lehmann F, Leihé B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976-7980
125. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185-1192
126. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA 92:432-436
127. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
128. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Human Immunol 52: 109-118
129. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841
130. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, Schreuder GMT. ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJM (1996) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 56:582-588
131. Brändie D, Brasseur F, Weynants P, Boon T, Van den Eynde BJ (1996) A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183:2501-2508
132. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89
133. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I. Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813
134. Boon T, Van der Bruggen P (1995) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
135. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078-8082
136. Marchand M, Weynants P, Rankin E, Arienti E, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885
137. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479-2483
138. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM (1996) Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918
139. Toes EM, Offringa R, Blom RJJ, Melief CJM, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860
140. Coulie PG, Lehmann F, Leihé B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976-7980
141. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185-1192
142. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA 92:432-436
143. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
144. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Human Immunol 52: 109-118
145. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841
146. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, Schreuder GMT. ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJM (1996) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 56:582-588
147. Brändie D, Brasseur F, Weynants P, Boon T, Van den Eynde BJ (1996) A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183:2501-2508
148. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89
149. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I. Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813
150. Boon T, Van der Bruggen P (1995) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
151. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078-8082
152. Marchand M, Weynants P, Rankin E, Arienti E, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885
153. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479-2483
154. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM (1996) Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918
155. Toes EM, Offringa R, Blom RJJ, Melief CJM, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860
156. Melief CJM, Offringa R, Toes REM, Kast WM (1996) Peptide-bused cancer vaccines. Curr Opin Immunol 8:651-657
157. Restifio NP (1996) The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol 8:658-663
158. Paterson Y, Ikonomidis G (1996) Recombinant Listeria monocytogenes cancer vaccines. Curr Opin Immunol 8:664-669
159. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG, Rutherford E, Hickling JK, Inglis SC (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527
160. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM (1996) Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580-589
161. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7-11
162. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 9:271-296
163. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297-1302
164. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97
165. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
166. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58
167. + T cells in vivo. Proc Natl Acad Sci USA 91:3077-3081
168. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258
169. Hintzen RQ, De Jong R, Lens SMA, Van Lier RA (1994) CD27: marker and mediator of T cell activation? Immunol Today 15:307-311
170. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ (1996) Immune regulations by CD40 and ist ligand gp39. Annu Rev Immunol 14:591-617
171. Hämmerling G, Schönrich G, Ferber L, Arnold B (1993) Peripheral tolerance as a multi-step mechanism. Immunol Rev 133:94-104
172. Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Differential costimulatory requirements in CD28-deficient mice. Science 261:609-612
173. Kündig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I (1993) Immune responses in IL-2 deficient mice. Science 262:1059-1061
174. + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177:1791-1796
175. Guerder S, Meyerhoff J, Flavell R (1994) The role of the T cell costimulator B7-1 in autoimmunity and in the induction and maintenance of tolerance to peripheral antigen. Immunity 1:155-156
176. Heath WR, Allison J, Hoffmann MW, Schönrich G, Hammerling G, Arnold B, Miller JFAP (1992) Autoimmune disease as a consequence of locally produced IL-2. Nature 359:547-549
177. Bluestone JA (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555-559
178. Kündig TM, Bachmann MF, DiPaolo C, Simard JJL, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, Zinkernagel RM (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1346
179. Kündig TM, Shahinian A, Kawai K, Mittrücker H-W, Sebzda E, Bachmann MF, Mak TW, Ohashi PS (1996) Duration of TCR Stimulation determines costimulatory requirement of T cells. Immunity 5:41-52
180. Gansbacher B, Zier K, Danials B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
181. Fearon ER, Pardoll DM, ltaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
182. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell 71:1093-1102
183. + T cells by B7-transfected melanoma cells. Science 259:368-370
184. Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G (1995) Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 25:1154-1162
185. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
186. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183:769-776
187. Matzinger P, Guerder S (1989) Does T cell tolerance require a dedicated antigen-presenting cell? Nature 338:74-76
188. Janeway CA Jr (1994) Thymic selection: two pathways to life and two to death. Immunity 1:3-6
189. Surh CD, Sprent J (1994) T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100-103
190. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045
191. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453-456
192. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
193. Rogel A, Popliker M, Webb CG, Oren M (1985) p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5:2851-2855
194. Milner J (1984) Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310:143-145
195. Terada N, Lucas JJ, Gelfand EW (1991) Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J Immunol 147:698-704
196. Houbiers JGA, Nijman HW, Burg SHvd, Drijfhout JW, Kenemans P, Velde CJvd, Brand A, Momburg F, Kast WM, Melief CJM (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wildtype p53. Eur J Immunol 23:2072-2077
197. Nijman HW, Houbiers JGA, Burg SHvd, Vierboom MPM, Kenemans P, Kast WM, Melief CJM (1993) Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 14:121-126
198. Nijman HW, Burg SHvd, Vierboom MPM, Houbiers JGA, Kast WM, Melief CJM (1994) p53, a potential target for tumor-directed T cells. Immunol Lett 40:171-178
199. Liu GY, Fairchild PJ, Smith RM, Prowie JR, Kioussis D, Wraith DC (1995) Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3:407-415
200. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357-1365
201. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc Natl Acad Sci USA 93:4781-4786
202. Pircher H, Rohrer UH, Moskophidis D, Zinkernagel RM, Hengartner H (1991) Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature 351:482-485
203. Karjalainen K (1994) High sensitivity, low affinity-paradox of T-cell receptor recognition. Curr Opin Immunol 6:9-12
204. Novotny J, Ganju RK, Smiley ST, Husseym RE, Luther MA, Rency MA, Siliciano RF, Reinherz EL (1991) A soluble single chain T cell receptor fragment endowed with antigen combining properties. Proc Natl Acad Sci USA 88:8646-8650
205. Brocker T, Peter A, Traunecker A, Karjalainen K (1993) New simplified molecular design for functional T cell receptor. Eur J Immunol 23:1435-1439
206. Chung S, Wucherpfennig KW, Friedman SM, Hafler DA, Strominger JL (1994) Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci USA 91:12654-12658
207. Sherman LA, Theobald M, Lustgarten J (1997) The use of HLA transgenic mice in identifying and targeting human tumor cell antigens. In: Eibl MM, Huber C, Peter HH, Wahn U (eds) Symposium in immunology VI, tumor immunology. Springer. Berlin Heidelberg New York, pp 41-48